Research programme: RNA-based antiviral therapeutics- Sarepta Therapeutics

Drug Profile

Research programme: RNA-based antiviral therapeutics- Sarepta Therapeutics

Alternative Names: Anti-IL-10 PMO; AVI-6001; AVI-6006; AVI-7012; NeuGene antiviral antisense compounds; NP AUG PMO; PB2 AUG PMO; Viral PMO-X for dengue - Sarepta Therapeutics

Latest Information Update: 16 Apr 2013

Price : $50

At a glance

  • Originator AVI BioPharma
  • Developer Sarepta Therapeutics
  • Class Antisense oligonucleotides
  • Mechanism of Action Genetic transcription inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Dengue
  • No development reported HIV infections; Influenza virus infections; Junin virus infections

Most Recent Events

  • 16 Apr 2013 No development reported - Preclinical for Influenza virus infections in USA (Parenteral)
  • 16 Apr 2013 No development reported - Preclinical for HIV infections in USA (Parenteral)
  • 16 Apr 2013 No development reported - Preclinical for Junin virus infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top